Daniela Molena, MD, of Memorial Sloan Kettering Cancer Center, discusses a comparison of the surgical journeys of patients with resectable gastric/gastroesophageal adenocarcinoma who either received fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) plus durvalumab or FLOT plus placebo in the MATTERHORN study (Abstract 353).
Marcel Verheij, MD, PhD, of Radboud University Medical Center, presents findings from the phase II CRITICS-II trial, which compared three preoperative regimens while omitting adjuvant treatment among patients with nonmetastatic resectable gastric cancer: chemotherapy, chemotherapy followed by chemoradiotherapy, and chemoradiotherapy (Abstract 283).
Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, reviews the goals of the upcoming phase III ARTEMIDE-HCC01 trial, which will examine the efficacy and safety of rilvegostomig (a novel bispecific anti–PD-1/anti-TIGIT antibody) plus bevacizumab with or without tremelimumab as first-line treatment for unresectable hepatocellular carcinoma (Abstract TPS612).
Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, outlines an assessment of baseline characteristics and safety outcomes in HIMALAYA trial participants who were rechallenged with tremelimumab after being treated with the STRIDE regimen (single dose of tremelimumab plus regular-interval durvalumab) (Abstract 541).
Samuel J. Klempner, MD, of Massachusetts General Hospital, discusses results from the phase II ILUSTRO trial, which evaluated the combination of the anti-CLDN18.2 antibody zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2-positive; HER2-negative; locally advanced, unresectable, or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma (Abstract LBA284).
Elena Elimova, MD, of Princess Margaret Cancer Centre, presents findings from the primary analysis of the phase III HERIZON-GEA-01 trial, which evaluated zanidatamab, a dual HER2-targeted bispecific antibody, plus chemotherapy with or without the PD-1 inhibitor tislelizumab vs trastuzumab plus chemotherapy as first line-regimens for HER2-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (Abstract LBA285).
